2,855
edits
Psychedelics: Difference between revisions
m
no edit summary
m (→Usage) |
mNo edit summary |
||
| Line 62: | Line 62: | ||
!Class | !Class | ||
!Drug | !Drug | ||
!Light High | !Light High Dose | ||
!Normal Dose | |||
!Normal | |||
!Maximum Safe dose | !Maximum Safe dose | ||
!Time to Onset | |||
!Duration of Experience | !Duration of Experience | ||
!Duration of Open State | !Duration of Open State | ||
| Line 73: | Line 72: | ||
|[[LSD]] | |[[LSD]] | ||
|20-50 μg | |20-50 μg | ||
| | |150 μg<ref>'''Dose-response relationships of LSD-induced subjective experiences in humans'''. Journal of neuropsychopharmacology Tim Hirschfeld, Johanna Prugger, Tomislav Majić & Timo T. Schmidt. Published: 09 May 2023, accessed on 4 Jun 2023 via <nowiki>https://www.nature.com/articles/s41386-023-01588-2</nowiki></ref> | ||
|1000-3000 μg | |1000-3000 μg | ||
|0.25-2 hours | |||
|6-11 hours | |6-11 hours | ||
|3 weeks | |3 weeks | ||
| Line 83: | Line 81: | ||
|[[DMT]] | |[[DMT]] | ||
|5-10 mg | |5-10 mg | ||
|40 mg | |40 mg | ||
|100 mg | |100 mg | ||
|Immediate | |||
|15-30 minutes | |15-30 minutes | ||
| - | | - | ||
| Line 93: | Line 90: | ||
|Psilocin | |Psilocin | ||
|5-10 mg | |5-10 mg | ||
|35 mg | |35 mg | ||
|150 mg | |150 mg | ||
|0.5 hours | |||
|3-6 hours | |3-6 hours | ||
|2 weeks | |2 weeks | ||
| Line 103: | Line 99: | ||
|Mescaline | |Mescaline | ||
|50-200 mg | |50-200 mg | ||
|400 mg | |400 mg | ||
|1000 mg | |1000 mg | ||
| | |||
|8-15 hours | |8-15 hours | ||
| - | | - | ||
| Line 112: | Line 107: | ||
| | | | ||
|Ibogaine | |Ibogaine | ||
| | | | ||
| | | | ||
| Line 122: | Line 116: | ||
|'''Empathogen''' | |'''Empathogen''' | ||
|[[MDMA]] | |[[MDMA]] | ||
| | | | ||
| | | | ||
| Line 132: | Line 125: | ||
| | | | ||
|2-CB | |2-CB | ||
| | | | ||
| | | | ||
| Line 142: | Line 134: | ||
|'''Dissociative''' | |'''Dissociative''' | ||
|[[Ketamine]] | |[[Ketamine]] | ||
| | | | ||
| | | | ||
| Line 152: | Line 143: | ||
| | | | ||
|Dextromethorphan | |Dextromethorphan | ||
| | | | ||
| | | | ||